Oppenheimer Reiterates Buy Rating on ODTX
Oppenheimer maintains its buy rating on ODTX with a $40 price target.
Key Points
- Oppenheimer reiterated its buy rating on ODTX on June 18, 2026, setting a price target of $40.
- Shares of ODTX are currently trading around $18.36, reflecting the market's response to recent analyst activity.
- Other analysts, including Wedbush and JP Morgan, have also initiated buy ratings on ODTX with targets of $30 and $26, respectively.
Analysts Set New Price Targets
On June 18, 2026, Oppenheimer reiterated its buy rating on ODTX, maintaining a price target of $40. This comes after previous actions by Oppenheimer, which initially set this target on June 2, 2026. Other firms have also shown interest in ODTX; Wedbush initiated coverage with a buy rating and a $30 price target on June 2, 2026, while JP Morgan set a buy rating with a $26 target the same day.
About ODTX
ODTX operates in the biotechnology sector, focusing on developing innovative therapies for various medical conditions. While specific details about its headquarters, CEO, or employee count are not provided, the company is known for its commitment to advancing healthcare solutions. Investors and analysts keep a close eye on ODTX due to its potential in the biotech industry.
Bottom Line
Oppenheimer's reiteration of its buy rating with a $40 target underscores confidence in ODTX's growth prospects. As shares trade around $18.36, the analyst coverage suggests optimism about the company’s future performance. Investors should note that these analyst ratings are based on available data and market conditions as of the report dates.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.